Department of Pharmaceutical Sciences, Regis University School of Pharmacy , Denver, CO, USA.
Expert Rev Clin Pharmacol. 2020 Aug;13(8):835-845. doi: 10.1080/17512433.2020.1721281. Epub 2020 Mar 2.
The concept of a cannabis 'entourage effect' was first coined as a hypothetical afterthought in 1998. Since then, multiple scientific reviews, lay articles, and marketing campaigns have promoted the effect as a wholly beneficial manifestation of polypharmacy expected to modulate the therapeutic effects of cannabis and its derivatives. There is reason to wonder at the authenticity of such claims.
A broad definition of the entourage effect is presented, followed by brief summaries of the nature of cannabis polypharmacy and the commonly cited contributing phytochemicals, with special attention to their attendant adverse effects. A critical analysis is then offered of the primary literature that is often portrayed as suggestive of the effect in existing reviews, with further studies being drawn from PubMed and Google Scholar searches. A final discussion questions the therapeutic value of the entourage effect and offers alternate perspectives on how it might be better interpreted.
Claims of a cannabis entourage effect invoke ill-defined and unsubstantiated pharmacological activities which are commonly leveraged toward the popularization and sale of ostensible therapeutic products. Overestimation of such claims in the scientific and lay literature has fostered their misrepresentation and abuse by a poorly regulated industry.
1998 年,首次提出大麻“伴随效应”的概念,当时只是作为一个假设。此后,多篇科学综述、通俗文章和营销活动都将该效应作为多药物协同作用的有益表现形式进行推广,认为其有望调节大麻及其衍生物的治疗效果。人们有理由对这些说法的真实性产生怀疑。
本文提出了伴随效应的广义定义,然后简要概述了大麻的多药物协同作用以及常被引用的相关植物化学物质的性质,特别关注它们伴随的不良反应。然后,对经常被现有综述描述为提示存在该效应的主要文献进行了批判性分析,并从 PubMed 和谷歌学术搜索中进一步寻找了其他研究。最后讨论了大麻伴随效应的治疗价值,并提出了如何更好地解释该效应的替代观点。
大麻伴随效应的说法援引了定义不明确且未经证实的药理学作用,这些作用通常被用来推广和销售所谓的治疗产品。在科学和通俗文献中对这些说法的过高估计,导致了它们在不受监管的行业中被错误地描述和滥用。